YZi Labs announced today its investment in regenerative medicine company Renewal Bio.

2025-11-11 13:06:25

Abstract generation in progress

Deep潮 TechFlow News, November 11th, YZi Labs announced today an investment in regenerative medicine company Renewal Bio. This is YZi Labs’ first biotech investment since expanding its investment scope in early 2025. Renewal Bio focuses on utilizing its proprietary Stembroid™ platform to generate human cells and tissues that are DNA-matched to patients from their own cells, aiming to address the global organ shortage crisis.

Over 150,000 organ transplants are performed worldwide each year, but less than 10% of the demand is met. Renewal Bio reprograms ordinary skin or blood cells into stem cells by simulating the early human developmental environment, producing various functional cells including hematopoietic, liver, heart, and pancreatic cells.

The company was co-founded in 2022 by Professor Jacob Hanna from the Weizmann Institute of Science and two PhD students in his laboratory, Vladislav Krupalnik and Ohad Gafni. This funding round will accelerate the preclinical development of Stembroid-derived hematopoietic stem cells for leukemia and immune disease treatments, as well as support laboratory infrastructure expansion.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.